Highlights Organon & Co.

Equities

OGN

US68622V1061

Market Closed - Nyse Other stock markets 21:00:02 09/05/2024 BST			5-day change	1st Jan Change
20.51 ^USD	+0.69%		+5.18%	+42.23%

05-08	Organon Reports Pricing of $1 Billion Senior Notes Offering	MT
05-08	Organon & Co. and Organon Foreign Debt Co-Issuer B.V. Announces Pricing of $1.0 Billion Senior Notes Offering	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Organon Reports Pricing of $1 Billion Senior Notes Offering	05-08	MT
Organon Plans Offerings of Secured, Unsecured Senior Notes Totaling $1 Billion	05-07	MT
Organon's Q1 Adjusted Earnings, Revenue Rise; 2024 Revenue Guidance, Quarterly Dividend Maintained	05-02	MT
Earnings Flash (OGN) ORGANON & CO. Reports Q1 Revenue $1.62B, vs. Street Est of $1.56B	05-02	MT
Earnings Flash (OGN) ORGANON & CO. Reports Q1 EPS $1.22, vs. Street Est of $0.93	05-02	MT
Organon & Co. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-02	CI
Organon & Co. Provides Earnings Guidance for the Year 2023	05-02	CI
Organon & Co Declares Quarterly Dividend on Common Stock, Payable on June 13, 2024	05-02	CI
Shanghai Henlius Biotech Denosumab Biosimilar HLX14 Meets Endpoint	04-08	MT
Aurobindo Pharma Gets US FDA Final Nod for Mometasone Furoate Monohydrate Nasal Spray	03-20	MT
US Department of Veterans Affairs (VA) Selects Organon & Co.'s HADLIMA, Replacing HUMIRA on Its National Formulary	02-20	CI
US Department of Veterans Affairs (VA) Selects Organon & Co.'s HADLIMA, Replacing HUMIRA on Its National Formulary	02-20	CI
Organon's Q4 Adjusted Earnings, Revenue Rise; 2024 Revenue Guidance Issued	02-15	MT
Organon & Co. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-15	CI
Earnings Flash (OGN) ORGANON & CO. Posts Q4 Revenue $1.6B, vs. Street Est of $1.48B	02-15	MT
Earnings Flash (OGN) ORGANON & CO. Reports Q4 EPS $0.88, vs. Street Est of $0.83	02-15	MT
Organon & Co. Declares Quarterly Dividend, Payable on March 14, 2024	02-15	CI
Organon & Co. Provides Earnings Guidance for the Year 2024	02-15	CI
Organon?S Xaciato (Clindamycin Phosphate) Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis in Females Aged 12 and Older	01-10	CI
Organon Affirms 2023 Revenue Outlook, Sets 2024 Guidance; Shares Jump	01-08	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Organon & Co.

Equities

OGN

US68622V1061

Highlights

Filters